Dyslipidemia

Featured Article
Praluent US List Price to Be Cut by 60%
Regeneron and Sanofi announced plans to offer the PCSK9 inhibitor, Praluent (alirocumab), at a significantly reduced price starting early March 2019 in an effort to make the drug more available to patients.
Importance of Identifying Cholesterol Problems Early in Life
In the second installment of this series, Amit Khera, MD, director of Preventive Cardiology and a Professor of Medicine at UT-Southwestern Medical Center in Dallas, discusses lifestyle risk, long-…
Patient Outcomes, Treatment Costs Related to Lipid Management
Amit Khera, MD, director of Preventive Cardiology and a Professor of Medicine at UT-Southwestern Medical Center in Dallas, explains how patient outcomes impact primary and secondary prevention and…

Newsfeed

Praluent US List Price to Be Cut by 60%
High Cholesterol Is Significantly Undertreated
Could “Good” Cholesterol Raise Infection Risk?
Variable Weight, BP, Cholesterol Raises Risk of Heart Attack
Are Guideline-Recommended Statin Treatment Thresholds Low?
2018 Cholesterol Guidelines Restore Thresholds, Address Additional Treatment Groups
Under Obamacare, Fewer Uninsured Hospitalizations for Heart Disease, Cancer
View More

Insights

Importance of Identifying Cholesterol Problems Early in Life
In the second installment of this series, Amit Khera, MD, director of Preventive Cardiology and a Professor of Medicine at UT-Southwestern Medical Center in Dallas, discusses lifestyle risk, long-term risk, and genetic cholesterol problems among…
Patient Outcomes, Treatment Costs Related to Lipid Management
Amit Khera, MD, director of Preventive Cardiology and a Professor of Medicine at UT-Southwestern Medical Center in Dallas, explains how patient outcomes impact primary and secondary prevention and related treatment costs.
View More
Back to Top